Adaptive Biotechnologies Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
7analysts covering
FY EPS (est.)
-$0.54next fiscal year
Monitoring Framework
Key Performance Indicators
clonoSEQ Test Volume Quarterly32.6KTarget: greater than 30% test volume growth
MRD Segment Revenue Quarterly67.1MTarget: $260 million to $270 million for FY 2026
Sequencing Gross Margin Quarterly70.0%
Clinical Average Selling Price (ASP) in the US Annually1.4KTarget: ~$1,400 per test for FY 2026
Watch Items
- Separation of MRD and Immune Medicine BusinessesTrigger: Identify preferred path to separate Immune Medicine by year-end 2026Action: Monitor the planned separation of the MRD diagnostics business from the Immune Medicine discovery platform.
- Dilution and Debt Restructuring from Convertible NotesTrigger: Issuance of $300 million convertible senior notes due 2031Action: Track the proposed convertible senior notes offering of $250 million and the unwinding of the $125 million royalty financing.
- Immune Medicine Data Licensing MilestonesTrigger: Pfizer Rheumatoid Arthritis partnership progress and new data licensing agreementsAction: Evaluate data licensing and partnerships for the Immune Medicine platform, including deals with Pfizer, while keeping cash burn tightly controlled.
Research as of 20 Jun 2026